{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:06:37Z","timestamp":1792710397700,"version":"4.5.0"},"reference-count":40,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.2169\/internalmedicine.4455-20","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T22:04:40Z","timestamp":1587593080000},"page":"1891-1897","source":"Crossref","is-referenced-by-count":6,"title":["Effective Treatment with Tocilizumab in a Rheumatoid Arthritis Patient Complicated with Human T-cell Leukemia Virus Type 1-associated Myelopathy"],"prefix":"10.2169","volume":"59","author":[{"given":"Chihiro","family":"Iwao","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Umekita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Rikitake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koushou","family":"Iwao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Rikitake","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Kariya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takajo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Okayama","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Iwanaga M, Watanabe T, Yamaguchi K. Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol 3: 322, 2012."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy\/tropical spastic paraparesis. Front Microbiol 3: 389, 2012.","DOI":"10.3389\/fmicb.2012.00389"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liao K, Karlson E. Classification and epidemiology of rheumatoid arthritis. In: Rheumatology. 5th ed. Hochberg MC, Silman AJ, Smolen JS, et al., Eds. ELSEVIER, London, 2010: 823-828.","DOI":"10.1016\/B978-0-323-06551-1.00081-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol 84: 327-335, 2012.","DOI":"10.1002\/jmv.23181"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet 389: 2338-2348, 2017.","DOI":"10.1016\/S0140-6736(17)31491-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Umekita K, Hidaka T, Miyauchi S, et al. Treatment with anti-tumor necrosis factor biologic agents in human T lymphotropic virus I-positive patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66: 788-792, 2014.","DOI":"10.1002\/acr.22205"},{"key":"7","unstructured":"7. Suzuki T, Fukui S, Umekita K, et al. Brief report: attenuated effectiveness of tumor necrosis factor inhibitors for anti-human T lymphotropic virus type I antibody-positive rheumatoid arthritis. Arthritis Rheumatol 70: 1014-1021, 2018."},{"key":"8","unstructured":"8. Terada Y, Kamoi K, Ohno-Matsui K, et al. Treatment of rheumatoid arthritis with biologics may exacerbate HTLV-1-associated condition:a case report. Medicine (Baltimore) 96: e6021, 2017."},{"key":"9","unstructured":"9. Osame M, Igata A, Matsumoto M, et al. HTLV-I-associated myelopathy (HAM), treatment trials, retrospective survey and clinical laboratory findings. Hematol Rev 3: 271-284, 1990."},{"key":"10","unstructured":"10. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010."},{"key":"11","unstructured":"11. Fujibayashi T, Sugai S, Miyasaka N, et al. Revised Japanese criteria for Sj\u00f6gren&apos;s symdrome (1999): availability and validity. Mod Rheumatol 14: 425-434, 2004."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakamura H, Shimizu T, Takagi Y, et al. Reevalution for clinical manifestations of HTLV-I-seropositive patients with Sj\u00f6gren&apos;s syndrome. BMC Muscloskelet Disord 16: 335, 2015.","DOI":"10.1186\/s12891-015-0773-1"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Mori S, Mizoguchi A, Kawabata M, et al. Bronchoalveolar lymphocytosis correlates with human T lymphotropic virus type I (HTLV-I) proviral DNA load in HTLV-I carriers. Thorax 60: 138-143, 2005.","DOI":"10.1136\/thx.2004.021667"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kawabata T, Higashimoto I, Takashima H, et al. Human T-lymphotropic virus type I (HTLV-I)-specific CD8+ cells accumulate in the lungs of patients infected with HTLV-I with pulmonary involvement. J Med Virol 84: 1120-1127, 2012.","DOI":"10.1002\/jmv.23307"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Prevoo ML, van&apos;t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48, 1995.","DOI":"10.1002\/art.1780380107"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kameda H, Fujii T, Nakajima A, et al. Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29: 31-40, 2019.","DOI":"10.1080\/14397595.2018.1472358"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Vasconcelos BHB, Callegari B, Costa KHA, et al. Balance impairments in patients with human T-cell lymphotropic virus type 1 infection. Sci Rep 9: 11456, 2019.","DOI":"10.1038\/s41598-019-47920-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Moore GR, Traugott U, Scheinberg LC, et al. Tropical spastic paraparesis: a model of virus-induced, cytotoxic T-cell-mediated demyelination? Ann Neurol 26: 523-530, 1989.","DOI":"10.1002\/ana.410260405"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Enose-Akahata Y, Jacobson S. Immunovirological markers in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). Retrovirology 16: 35, 2019.","DOI":"10.1186\/s12977-019-0499-5"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ohama E, Horikawa Y, Shimizu T, et al. Demyelination and remyelination in spinal cord lesions of human lymphotropic virus type I-associated myelopathy. Acta Neuropathol 81: 78-83, 1990.","DOI":"10.1007\/BF00662641"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Matsuura E, Kubota R, Tanaka Y, et al. Visualization of HTLV-1-specific cytotoxic T lymphocytes in the spinal cords of patients with HTLV-1-associated myelopathy\/tropical spastic paraparesis. J Neuropathol Exp Neuro 74: 2-14, 2015.","DOI":"10.1097\/NEN.0000000000000141"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Narv\u00e1ez J, Sirvent E, Narv\u00e1ez JA, et al. Usefulness of magnetic resonance imaging of the hand versus anticyclic citrullinated peptide antibody testing to confirm the diagnosis of clinically suspected early rheumatoid arthritis in the absence of rheumatoid factor and radiographic erosions. Semin Arthritis Rheum 38: 101-109, 2008.","DOI":"10.1016\/j.semarthrit.2007.10.012"},{"key":"23","unstructured":"23. Solau-Gervais E, Legrand JL, Cortet B, Duquesnoy B, Flipo RM. Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study. J Rheumatol 33: 1760-1765, 2006."},{"key":"24","unstructured":"24. Freeston JE, Wakefield RJ, Conaghan PG, et al. A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment tools. Ann Rheum Dis 69: 417-419, 2010."},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Minowa K, Ogasawara M, Murayama G, et al. Predictive grade of ultrasound synovitis for diagnosing rheumatoid arthritis in clinical practice and the possible difference between patients with and without seropositivity. Mod Rheumatol 26: 188-193, 2016.","DOI":"10.3109\/14397595.2015.1069457"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sato K, Maruyama I, Maruyama Y, et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum 34: 714-721, 1991.","DOI":"10.1002\/art.1780340612"},{"key":"27","unstructured":"27. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69: 631-637, 2010."},{"key":"28","unstructured":"28. Wolfe F, Caplan L, Michaud K. et al. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54: 628-634, 2006."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Alarc\u00f3n G, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127: 356-364, 1997.","DOI":"10.7326\/0003-4819-127-5-199709010-00003"},{"key":"30","unstructured":"30. Ohosone Y, Okano Y, Kameda H, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 24: 2299-2303, 1997."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Mohan N, Edwaeds ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritis Rheum 44: 2862-2869, 2001.","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Bosch X, Saiz A, Ramos-Casals M. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol 7: 165-172, 2011.","DOI":"10.1038\/nrneurol.2011.1"},{"key":"33","unstructured":"33. Mori N, Shirakawa F, Abe M, et al. Human T-cell leukemia virus type I tax transactivates the interleukin-6 gene in human rheumatoid synovial cells. J Rheumatol 22: 2049-2054, 1995."},{"key":"34","unstructured":"34. Horiuchi S, Yamamoto N, Dewan MZ, et al. Human T-cell leukemia virus type-I Tax induces expression of interleukin-6 receptor (IL-6R): Shedding of soluble IL-6R and activation of STAT3 signaling. Int J Cancer 119: 823-830, 2006."},{"key":"35","doi-asserted-by":"publisher","unstructured":"35. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood 116: 1211-1219, 2010.","DOI":"10.1182\/blood-2009-12-257410"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Grassi MF, Olavarria VN, Kruschewsky Rde A, et al. Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP. J Med Virol 83: 1269-1274, 2011.","DOI":"10.1002\/jmv.22087"},{"key":"37","unstructured":"37. Umekita K, Hashiba Y, Kariya Y, et al. The time-sequential changes of risk factors for adult T-cell leukemia development in human T-cell leukemia virus-positive patients with rheumatoid arthritis: a retrospective cohort study. Mod Rheumatol 29: 795-801, 2019."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Takajo I, Umekita K, Ikei Y, Oshima K, Okayama A. Adult T-cell leukemia\/lymphoma as a methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis. Intern Med 57: 2071-2075, 2018.","DOI":"10.2169\/internalmedicine.0308-17"},{"key":"39","unstructured":"39. Hashiba Y, Hidaka T, Umekita K, et al. Remission of chronic type ATL in a patient with rheumatoid arthritis after withdrawing methotrexate and infliximab combination therapy: a case report. Modern Rheumatol Case Rep 2: 9-13, 2018."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Nakamura H, Ueki Y, Saito S, et al. Development of adult T-cell leukemia in a patient with rheumatoid arthritis treated with tocilizumab. Intern Med 52: 1983-1986, 2013.","DOI":"10.2169\/internalmedicine.52.0468"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/15\/59_4455-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T03:33:34Z","timestamp":1596252814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/15\/59_4455-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,1]]},"references-count":40,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4455-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,1]]}}}